Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: A paired biopsy study

Journal of Bone and Mineral Research, 07/08/2013

The spectrum of therapeutic options and the amount of clinical trials for male osteoporosis (mOP) is lower than those for postmenopausal osteoporosis. The bone mineralization density distribution (BMDD) findings are in line with the reduction of bone turnover markers and the increase in BMD by ibandronate (IBN) in the patients and suggest that latter mainly reflect the increase in matrix mineralization and the reduction of cortical porosity in this cohort with male osteoporosis (mOP).

Print Article Summary Cat 2 CME Report